Investors Are Watching: Spirit Realty Capital, Inc. (NYSE:SRC), GALAPAGOS NV (NASDAQ:GLPG), The Charles Schwab Corporation (NYSE:SCHW), Cullen/Frost Bankers (NYSE:CFR), Pacira Pharmaceuticals (NASDAQ:PCRX)

Spirit Realty Capital, Inc. (NYSE:SRC) belongs to Financial sector. Its net profit margin is -3.70% and weekly performance is 2.63%. On last trading day company shares ended up $10.14. Spirit Realty Capital, Inc. (NYSE:SRC) distance from 50-day simple moving average (SMA50) is -3.75%. Spirit Realty Capital, Inc. (NYSE:SRC) announced that it plans to release its 2015 second quarter financial results after the close of the stock market on Thursday, August 6, 2015.

GALAPAGOS NV (NASDAQ:GLPG) shares moved up 1.07% in last trading session and ended the day at $53.06. On 19 June, Galapagos NV (NASDAQ:GLPG) announced a share capital increase arising from warrant exercises. Since its inception in 1999, Galapagos has used warrant plans to incentivize personnel and management and have them share in the success of the company. Following warrant exercises during the exercise period from 2 June 2015 through 15 June 2015, Galapagos issued 491,406 new ordinary shares for a total capital increase (including issuance premium) of EUR4,395,172.45.

On 10 July, The Charles Schwab Corporation (NYSE:SCHW) shares increased 2.02% and was closed at $32.83. SCHW EPS growth in last 5 year was 7.10%. The Charles Schwab Corporation (NYSE:SCHW) year to date (YTD) performance is 9.19%. The Charles Schwab Corporation (NYSE:SCHW) announced that it has scheduled a Business Update for institutional investors on Friday, July 24, 2015. This Update is designed to help the investment community keep abreast of recent developments and management’s strategic focus.

Cullen/Frost Bankers, Inc. (NYSE:CFR) ended the last trading day at $75.06. Company weekly volatility is calculated as 2.03% and price to cash ratio as 1.23. Cullen/Frost Bankers, Inc. (NYSE:CFR) showed a weekly performance of -3.15%. Zacks upgraded shares of Cullen/Frost Bankers (NYSE:CFR) from a hold rating to a buy rating in a report issued on Wednesday, Marketbeat.com reports. They currently have $89.00 target price on the stock.

Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) shares moved up 0.30% in last trading session and ended the day at $67.54. PCRX Gross Margin is 64.90% and its return on assets is -3.90%. Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) quarterly performance is -22.96%.

Leave a Reply

Your email address will not be published. Required fields are marked *